What is the appropriate evaluation and management for a patient with elevated eosinophils, neutrophils, and monocytes on a complete blood count?

Evaluation and Management of Elevated Eosinophils, Neutrophils, and Monocytes

When you encounter simultaneous elevation of eosinophils, neutrophils, and monocytes, prioritize ruling out myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase (TK) fusion genes first, followed by secondary causes including helminth infections, allergic conditions, and drug reactions. 1

Initial Risk Stratification

Immediately assess for life-threatening complications:

• Cardiac involvement: Check troponin, NT-proBNP, and echocardiogram for endomyocardial thrombosis/fibrosis 1
• Pulmonary involvement: Evaluate for dyspnea, cough, and interstitial infiltrates 1
• Neurologic involvement: Screen for CNS symptoms 2
• GI involvement: Assess for abdominal pain and GI bleeding 3

If end-organ damage is present or suspected, initiate oral or high-dose IV corticosteroids immediately while completing diagnostic workup 1

Diagnostic Algorithm by Eosinophil Count

Absolute Eosinophil Count (AEC) Classification:

• Mild eosinophilia: 500-1,499 cells/μL
• Moderate eosinophilia: 1,500-4,999 cells/μL
• Severe eosinophilia: ≥5,000 cells/μL 2, 4

The concurrent elevation of neutrophils and monocytes alongside eosinophilia strongly suggests either a myeloproliferative neoplasm or advanced secondary cause 1, 3

Essential First-Line Testing

1. Peripheral Blood Smear (Critical)

Look for:

• Blast cells (>2% suggests CEL or acute leukemia) 3
• Myeloid immaturity and dysplasia 1
• Basophilia (suggests myeloproliferative disorder) 1

2. Molecular/Cytogenetic Testing (Priority for AEC >1,500)

Order immediately:

• FIP1L1-PDGFRA fusion (most common, highly responsive to imatinib) 1
• PDGFRB rearrangement 1
• FGFR1 rearrangement 1
• PCM1-JAK2 fusion 1
• BCR-ABL1 (if features suggest CML) 1

These TK fusion genes define specific myeloid/lymphoid neoplasms requiring targeted therapy 1

3. Bone Marrow Biopsy (Required if AEC >1,500 for >1 month)

Perform when:

• Peripheral blasts present
• Cytopenia alongside leukocytosis
• Dysplastic features on smear
• Molecular testing unavailable 3

Diagnostic criteria for CEL: Blasts 5-20% in marrow OR >2% blasts in peripheral blood with AEC >1,500 3

4. Helminth Screening (Essential in travelers/migrants)

• Strongyloides stercoralis serology (critical—can cause fatal hyperinfection if immunosuppressed) 2
• Schistosoma serology (associated with bladder cancer long-term) 2
• Filarial serology only if West Africa exposure 2
• Stool ova and parasites (3 samples) 2

5. Allergy/Atopy Assessment

• Total IgE and specific IgE to Aspergillus (for ABPA) 5
• Review for asthma, eczema, drug reactions 5
• Atopic diseases cause 53.4% of eosinophilia cases but rarely cause concurrent neutrophilia/monocytosis 5

6. Additional Testing Based on Clinical Context

• ANCA (for EGPA if asthma + vasculitis features) 5
• Serum tryptase (for systemic mastocytosis) 5
• HIV, HTLV-1 (immunodeficiency-associated eosinophilia) 2
• Vitamin B12 (markedly elevated in myeloproliferative disorders) 6

Treatment Approach

For Confirmed Myeloid/Lymphoid Neoplasms with TK Fusions:

PDGFRA rearrangement (e.g., FIP1L1-PDGFRA):

• Imatinib 100 mg daily for chronic phase 1
• Add corticosteroids for 7-10 days if cardiac involvement 1
• Cardiology consultation mandatory if troponin elevated 1
• Achieves durable molecular remissions in vast majority 1

PDGFRB rearrangement:

• Imatinib 400 mg daily initially, reduce to 100 mg after complete response 1

Blast phase disease:

• Imatinib 400 mg daily (chemotherapy rarely achieves durable remission) 1

For Secondary Eosinophilia:

Asymptomatic eosinophilia in travelers/migrants (age >24 months):

• Empirical treatment: Albendazole 400 mg single dose PLUS Ivermectin 200 μg/kg single dose 2

Strongyloides confirmed:

• Ivermectin 200 μg/kg daily for 2 days 2
• Recheck serology to confirm cure

Allergic/atopic causes:

• Treat underlying condition (inhaled corticosteroids for asthma, etc.) 5
• Remove offending drugs 5

For Idiopathic Hypereosinophilia:

If AEC ≥1,500 for >3 months with no identifiable cause after complete workup:

• Refer to hematology 2
• Monitor for end-organ damage every 3-6 months 2
• Consider corticosteroids if organ involvement develops 1

Critical Pitfalls to Avoid

1. Never assume allergy alone explains AEC >1,500—hypereosinophilia requires full malignancy workup 4

2. Never start immunosuppression before excluding Strongyloides—risk of fatal hyperinfection syndrome 2

3. Don't delay imatinib if TK fusion confirmed—early treatment prevents irreversible cardiac damage 1

4. Concurrent neutrophilia + monocytosis + eosinophilia is NOT typical of allergy—strongly suggests myeloproliferative process 1, 3

5. Check cardiac biomarkers even if asymptomatic—eosinophil-mediated cardiac damage can be subclinical 1

Multidisciplinary Consultation

Mandatory consultations:

• Hematology/oncology: All cases with AEC >1,500 or abnormal peripheral smear 1
• Cardiology: Any cardiac symptoms, elevated troponin/NT-proBNP, or abnormal echo 1
• Infectious disease: Travel history or suspected parasitic infection 1, 2
• Allergy/immunology: Suspected atopic disease or ABPA 5

The combination of elevated eosinophils with neutrophils and monocytes narrows your differential significantly toward myeloproliferative disorders—molecular testing for TK fusions should be your first priority after ruling out acute end-organ damage 1, 3